Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 18/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24045084 | 1.00 | KMT2A (0.44) | KMT2ADGAT2NAAA | |
| SCHEMBL30314754 | 0.88 | DGAT2 (0.47) | KMT2ADGAT2 | |
| SCHEMBL24045018 | 0.88 | DGAT2 (0.47) | KMT2ADGAT2 | |
| SCHEMBL30314667 | 0.87 | DGAT2 (0.55) | KMT2ADGAT2 | |
| SCHEMBL24045002 | 0.87 | DGAT2 (0.55) | KMT2ADGAT2 | |
| SCHEMBL26564988 | 0.87 | DGAT2 (0.50) | KMT2ADGAT2 | |
| SCHEMBL24045129 | 0.86 | DGAT2 (0.53) | KMT2ADGAT2 | |
| SCHEMBL30314752 | 0.86 | DGAT2 (0.53) | KMT2ADGAT2 | |
| SCHEMBL24045029 | 0.86 | DGAT2 (0.44) | KMT2ADGAT2 | |
| SCHEMBL24045035 | 0.86 | DGAT2 (0.47) | KMT2ADGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448384-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240059700-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-02-22 | — | — | US | disclosed |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4153584-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059700-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | KMT2A 693/4885DGAT2 1/4885NAAA 405/4885 |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | KMT2A 645/4885DGAT2 1/4885NAAA 413/4885 |
| US-12448384-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | KMT2A 645/4885DGAT2 1/4885NAAA 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.